Key facts
- CereVasc, Inc. announced an $85 million Series C financing round.
- The financing round was over-subscribed.
- Piper Sandler Merchant Banking led the financing round.
- Johnson & Johnson Innovation – JJDC, Inc. and Medtronic participated as new investors.
- Bain Capital Life Sciences and Perceptive Advisors participated as existing investors.
CereVasc, Inc., a company focused on developing treatments for normal pressure hydrocephalus, has successfully closed an $85 million Series C financing round. The round was significantly over-subscribed, indicating strong investor confidence. Piper Sandler Merchant Banking served as the lead investor. New investors joining the round include Johnson & Johnson Innovation – JJDC, Inc., the corporate venture capital arm of Johnson & Johnson, and Medtronic. Existing investors, such as Bain Capital Life Sciences and Perceptive Advisors, also participated, demonstrating continued support for the company's mission. The funds are earmarked to advance CereVasc's novel eShunt® System, designed for the treatment of normal pressure hydrocephalus.